UC San Diego scientists have launched a clinical trial to investigate whether a drug approved for treating high blood pressure might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.
ACE inhibitor drugs like Ramipril are widely used for various cardiovascular conditions; researchers want to see if they might also provide benefit to patients infected by SARS-CoV-2
UC San Diego Health has launched a Phase III clinical trial to assess whether a medication used to treat rheumatoid might also have therapeutic value for patient with COVID-19 who have developed or are at high risk of developing serious lung damage from SARS-CoV-2 infections.
Clinical trials at UC San Diego Health and elsewhere will assess whether tocilizumab can reduce out-of-control inflammation that damages lungs and increases risks for ventilation and death
Researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.
Researchers at UC San Diego School of Medicine and three German universities describe an underlying biological basis for myalgic encephalomyelitis/chronic fatigue syndrome, illustrating how efforts by the body to boost immune system protections can come at physiological cost elsewhere.
IN THE NEWS: When New York City's hospitals were overwhelmed with COVID-19 patients this spring, UCI Health trauma surgeon Dr. Sebastian Schubl answered his mentor's call for help. Schubl treated many patients during his week of 12-hour shifts in the intensive care unit at New York-Presbyterian Hospital. It was a…
Health Media Contacts
Find the best contact for health-related media inquiries.
